Northwest Biotherapeutics Inc NWBO

Healthcare Biotechnology

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct, is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and included treatment of a diverse range of more than a dozen types of cancers. The Company’s wholly owned subsidiaries include Flaskworks, LLC, Northwest Biotherapeutics Limited, Aracaris Capital, Ltd, Northwest Biotherapeutics B.V., and NW Bio GmbH.

OTCQB:NWBO - Post by User

Northwest Biotherapeutics Inc

Bullboard Posts

Post by pericles1on Sep 17, 2014 2:32am

109 Views

Post# 22942899

UK PRESENTATION!

I think Linda gave her best presentation since I have owned the stock. It was excellent news but the market did not give it much weight. She also spent a lot of time talking about direct. She stressed that they are learning a lot in phase one, seeming to indicate that phase II should be even better. She also seemed to pinpoint first indications such as sarcoma, pancreatic and colon, and multiple sites will be used for injections. Overall I am pleased and may even buy more.

Bullboard Posts

Understanding tax loss season and the “Santa Claus rally”